StockData
Legend Biotech Corp logo

Legend Biotech Corp (LEGN) stock

LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026Score 3/30
$16.11+0.12 (+0.75%)

Close on Nov 17, 2026Market cap $2.98BP/E –Yield –

Legend Biotech total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Legend Biotech's total debt was $156.40M at Jun 30, 2026. For fiscal 2025 it was $319.10M, up 5.9% from the year before. The highest annual figure on record is $319.10M in fiscal 2025.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$319.10M+5.9%
FY2024Dec 31, 2024$301.20M+7.1%
FY2023Dec 31, 2023$281.33M+7.8%
FY2022Dec 31, 2022$260.93M+116.6%
FY2021Dec 31, 2021$120.46M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$156.40M-49.6%
Q1 FY2026Mar 31, 2026$266.00M-13.0%
Q4 FY2025Dec 31, 2025$319.10M+5.9%
Q3 FY2025Sep 30, 2025$314.80M+6.1%
Q2 FY2025Jun 30, 2025$310.26M+6.4%
Q1 FY2025Mar 31, 2025$305.75M+6.8%
Q4 FY2024Dec 31, 2024$301.20M+7.1%
Q3 FY2024Sep 30, 2024$296.62M+7.5%
Q2 FY2024Jun 30, 2024$291.56M+7.7%
Q1 FY2024Mar 31, 2024$286.40M+9.8%
Q4 FY2023Dec 31, 2023$281.33M+133.5%
Q3 FY2023Sep 30, 2023$275.91M+1493.9%
Q2 FY2023Jun 30, 2023$270.61M–
Q4 FY2022Dec 31, 2022$260.93M–
Q4 FY2021Dec 31, 2021$120.46M–
Q2 FY2021Jun 30, 2021$17.31M–

More Legend Biotech figures

See a number that looks wrong?